Veterinary Medicines

Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

Authorised
  • Dexamethasone sodium phosphate
Download as PDF

Product identification

Medicine name:
Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats
Dexaject 2 mg/ml injeksjonsvæske, oppløsning til storfe, hest, gris, hund og katt
Active substance:
  • Dexamethasone sodium phosphate
Target species:
  • Horse
  • Cattle
  • Dog
  • Cat
  • Pig
Route of administration:
  • Intraarticular use
  • Intramuscular use
  • Intravenous use

Product details

Active substance and strength:
  • Dexamethasone sodium phosphate
    2.63
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intraarticular use
    • Horse
      • Meat and offal
        8
        day
  • Intramuscular use
    • Cattle
      • Meat and offal
        8
        day
      • Milk
        72
        hour
    • Dog
    • Horse
      • Meat and offal
        8
        day
    • Cat
    • Pig
      • Meat and offal
        2
        day
  • Intravenous use
    • Horse
      • Meat and offal
        8
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QH02AB02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Package description:
  • Cardboard box with 1 colourless, type I glass vial of 50 ml which is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.
  • Cardboard box with 1 colourless, type I glass vial of 100 ml which is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Dopharma Research B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Dopharma B.V.
Responsible authority:
  • Norwegian Medicines Agency
Authorisation number:
  • 17-11960
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0293/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Norway
  • Poland
  • Romania
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download
Norwegian (PDF)
Published on: 6/06/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 7/11/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."